Abstract: A compound of formula (I) or a salt thereof: ##STR1## Wherein: P represents a quinoline or isoquinoline residue; R.sub.1 is hydrogen or C.sub.1-6 alkyl; R.sub.2, R.sub.3, R.sub.10, R.sub.11 are independently hydrogenR.sub.1 is hydrogen or C.sub.1-6 alkyl; R.sub.2, R.sub.3, R.sub.10, R.sub.11 are independently hydrogen or C.sub.1-6 alkyl, or R.sub.10 and R.sub.11 together form a bond, or R.sub.2 and R.sub.10 or R.sub.3 and R.sub.11 together form a C.sub.2-6 alkylene chain. R.sub.4 is hydrogen, C.sub.1-6 alkyl, halogen, NR.sub.8 R.sub.9, OR.sub.12 or COOR.sub.12, where R.sub.8 R.sub.9 and R.sub.12 are independently hydrogen or C.sub.1-6 alkyl; R.sub.5 and R.sub.6 are independently hydrogen or C.sub.1-6 alkyl; and R.sub.7 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen; and wherein the urea moiety is attached at the 4-, 5- or 6-position of the indoline ring, which has been found to have 5HT.sub.1c receptor antagonist activity.

Abstract: Tetrahydrobenzothienopyridines of formula (I), ##STR1## wherein, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.8 and R.sub.9 are as defined in the specification and pharmaceutical compositions containing such compounds are of use in treating anxiety, convulsion and sleep disorders.

Abstract: A class of compounds identified as N-(1-methyl-1H-indol-5-yl)-(2,3 or 4-pyridyl)ureas, derivatives thereof, methods for their preparation, pharmaceutical compositions containing same and their 5-HT receptor antagonist activity are believed to be of potential use in the treatment of a variety of CNS disorders are described herein.

Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, phenyl or phenyl C.sub.1-4 alkyl wherein the phenyl moiety is optionally substituted by one or more C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, hydroxy, C.sub.2-7 alkanoyl, halo, trifluoromethyl, nitro, amino optionally substituted by one or two C.sub.1-6 alkyl groups or by C.sub.2-7 alkanoyl, cyano, carbamoyl or carboxy groups;R.sub.2, R.sub.3 and R.sub.4 are independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylthio, C.sub.2-7 alkanoyl, trifluoromethyl, cyano, carbamoyl and carboxy, and phenyl or phenyl C.sub.1-4 alkyl in which any phenyl moiety is optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkoxy carbonyl, C.sub.1-6 alkylthio, hydroxy, C.sub.2-7 alkanoyl, chloro, fluoro, trifluoromethyl, nitro or amino optionally substituted by one or two C.sub.1-6 alkyl groups or by C.sub.

Abstract: A compound for formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and Z are described in claim 1.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, phenyl or phenyl C.sub.1-4 alkyl wherein the phenyl moiety is optionally substituted by one or more C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, hydroxy, C.sub.2-7 alkanoyl, halo, trifluoromethyl, nitro, amino optionally substituted by one or two C.sub.1-6 alkyl groups or by C.sub.2-7 alkanoyl, cyano, carbamoyl or carboxy groups; R.sub.2, R.sub.3 and R.sub.4 are independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylthio, hydroxy, C.sub.2-7 alkanoyl, chloro, fluoro, trifluoromethyl, nitro, amino optionally substituted by one or two C.sub.1-6 alkyl groups or by C.sub.2-7 alkanoyl, cyano, carbamoyl and carboxy, and phenyl, phenyl C.sub.1-4 alkyl or phenyl C.sub.1-4 alkoxy in which any phenyl moiety is optionally substituted by any of these groups; R.sub.5 and R.sub.6 are independently selected from hydrogen, C.sub.